Kamada Ltd
KMDA
KMDA: Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
moreShow KMDA Financials
Recent trades of KMDA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by KMDA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases Mar. 30, 2021
-
Patent Title: Compositions derived from cohn fraction paste and use thereof Jul. 28, 2020
-
Patent Title: Therapy and prophylaxis of infectious disease caused by zika virus Jun. 23, 2020
-
Patent Title: Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases Jul. 05, 2011
-
Patent Title: Large scale preparation of alpha-1 proteinase inhibitor and use thereof Feb. 01, 2011
Federal grants, loans, and purchases
Followers on KMDA's company Twitter account
Number of mentions of KMDA in WallStreetBets Daily Discussion
Recent insights relating to KMDA
Recent picks made for KMDA stock on CNBC
ETFs with the largest estimated holdings in KMDA
Flights by private jets registered to KMDA